Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMD14 | O00487 | 2/20 | 0.56 |
| ▸ | STAMBP | O95630 | 1/20 | 0.56 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.56 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.46 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.46 |
| ▸ | F7 | P08709 | 1/20 | 0.46 |
| ▸ | F3 | P13726 | 1/20 | 0.46 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.46 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.46 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | ACP1 | P24666 | 1/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | NNMT | P40261 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27599972 | 0.98 | PSMD14 (0.55) | PSMD14STAMBPCOPS5SIRT2SIRT1 | |
| Hydrochloric Acid SCHEMBL14966721 | 0.98 | PSMD14 (0.55) | PSMD14STAMBPCOPS5SIRT2SIRT1 | |
| Formic Acid SCHEMBL30468936 | 0.94 | PSMD14 (0.51) | PSMD14STAMBPCOPS5SIRT2SIRT1 | |
| Trifluoroacetic Acid SCHEMBL5265398 | 0.90 | PSMD14 (0.48) | PSMD14STAMBPCOPS5SIRT2SIRT1 | |
| SCHEMBL124592 | 0.84 | MGAM (0.59) | PSMD14STAMBPCOPS5ACP1MGAM | |
| SCHEMBL30392839 | 0.84 | MGAM (0.59) | PSMD14STAMBPCOPS5ACP1MGAM | |
| SCHEMBL21358860 | 0.83 | PSMD14 (0.61) | PSMD14STAMBPCOPS5SIRT2SIRT1 | |
| Hydrochloric Acid SCHEMBL9378228 | 0.83 | MGAM (0.57) | PSMD14STAMBPCOPS5ACP1MGAM | |
| Hydrochloric Acid SCHEMBL7010614 | 0.83 | MGAM (0.57) | PSMD14STAMBPCOPS5ACP1MGAM | |
| SCHEMBL30763995 | 0.82 | ACP1 (0.48) | PSMD14STAMBPCOPS5ACP1HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-07 | — | — | US | claimed |
| CN-114423757-B | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors | 百时美施贵宝公司 | 2024-07-02 | — | — | CN | claimed |
| CN-110934876-B | C 27 H 27 N 7 O 2 Application of S in preparation of medicament for inhibiting organ allograft rejection | 中山大学·深圳 | 2023-07-28 | — | — | CN | claimed |
| CN-115583948-A | Novel crystalline forms of POL1 inhibitor | 皮梅拉股份有限公司 | 2023-01-10 | — | — | CN | claimed |
| EP-3999508-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2022-05-25 | — | — | EP | claimed |
| CN-114423757-A | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors | 百时美施贵宝公司 | 2022-04-29 | — | — | CN | claimed |
| CN-108904508-B | Novel application of Polymerase I inhibitor | 中山大学 | 2021-03-12 | — | — | CN | claimed |
| WO-2021011724-A1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-01-21 | — | — | WO | claimed |
| EP-3638672-A1 | CHEMICAL COMPOUNDS AS H-PGDS INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-04-22 | — | — | EP | claimed |
| CN-110709400-A | Novel crystalline forms of POL1 inhibitor | 皮梅拉股份有限公司 | 2020-01-17 | — | — | CN | claimed |
| EP-2401275-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | Respiratorius AB (SE) | 2012-01-04 | — | — | EP | claimed |
| WO-2010097410-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | RESPIRATORIUS AB (SE) | 2010-09-02 | — | — | WO | claimed |
| EP-1866305-A1 | 1,7-NAPHTHYRIDINES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-12-19 | — | — | EP | claimed |
| WO-2006097340-A1 | 1,7-NAPHTHYRIDINES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-21 | — | — | WO | claimed |
| WO-2004019933-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | claimed |
| WO-2004019940-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | claimed |
| US-20030207880-A1 | Heterocycle carboxamides as antiviral agents | BUNDY GORDON L (US) | 2003-11-06 | — | — | US | claimed |
| CN-1418214-A | 4-Hydroxy-1, 8-Naphthyridine-3-carboxamides as antiviral agents | UPJOHN CO (US) | 2003-05-14 | — | — | CN | claimed |
| EP-1301493-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-16 | — | — | EP | claimed |
| WO-2002004444-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | ZC3HAV1, CCR1, CCR6 | PSMD14 4789/4885STAMBP 4739/4885COPS5 1389/4885 |
| US-20030207880-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | PSMD14 2571/4885STAMBP 4106/4885COPS5 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.